Although many small molecule inhibitors targeting the PI3K/AKT/mTOR signaling pathway were pre-clinically studied, only some of the PI3K and mTOR inhibitors are currently approved for the treatment of human cancers in the clinic. This evidence concerns the gene AKT1 and cancer.